CGT Wiki

Applicable species: mice, rats; NHP/pig data are limited [12-50,12-51]. Dose range: retrograde ureter 1×10^11 vg/kidney; renal vein 1×10^11-1×10^12 vg/kidney (about half the tail vein dose); rat 1×10^11-5×10^11 vg/kidney [12-50,12-51]. Injection volume: approximately 100 μL/kidney; rat 100-200 μL/kidney [12-50,12-51]. Needle: tuberculin syringe + 33 G needle (retrograde ureter, fixed with 6-0 silk thread); 30-31 G needle for renal vein [12-50,12-51]. Speed: Slow retrograde ureteral injection of approximately 50-100 μL/min [12-50,12-51]. Anesthesia: sodium pentobarbital 50 mg/kg IP, 37°C thermostat [12-50,12-51]. Key points of operation: Retrograde ureter requires a microvascular clamp to clamp the distal ureter and renal artery, first aspirate urine and then slowly inject it retrogradely into the renal pelvis, and keep the clamp for 30 minutes to maximize exposure; after clamping the renal artery/vein via the renal vein route, slowly inject 100 μL through the proximal end of the renal vein [12-50,12-51]. Coverage: AAV9 can transduce all nephron segments (proximal tubules, distal tubules, collecting ducts, podocytes), and can be segment-specific with segment-specific promoters (SGLT2→PT, etc.); extrarenal expression is minimal, and liver off-targeting is significantly lower than systemic administration; expression peaks in 2-4 weeks [12-50,12-51].